Search research articles
Contact Us
Filters
Showing results (111-120 of 186) with videos related to
Page
of 19
Sort By:
Journal of Clinical Medicine
|
August 10, 2019
Detection of <i>TP53</i> and <i>PIK3CA</i> Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis
Begona Jimenez Rodriguez, Gema Diaz Córdoba, Alicia Garrido Aranda, et al.
Lancet (London, England)
|
February 2, 2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 11, 2009
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer
Stephen Chan, Gilles Romieu, Jens Huober, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 2009
Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer
Luca Gianni, José Baselga, Wolfgang Eiermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 11, 2010
Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer
Adel Tabchy, Vicente Valero, Tatiana Vidaurre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 2, 2009
Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study
Javier Cortes, Serena Di Cosimo, Miguel A Climent, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 16, 2015
Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer
Amir Sonnenblick, Prudence A Francis, Hatem A Azim, et al.
Journal of the National Cancer Institute
|
September 18, 2015
Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis
Milica Pavlovic, Anna Arnal-Estapé, Federico Rojo, et al.
The Lancet. Oncology
|
March 25, 2014
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, et al.
Cancer
|
June 7, 2005
The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study
Alberto J Montero, Roman Rouzier, Ana Lluch, et al.
Page
of 19
Search research articles
Search
Showing results (111-120 of 186) with videos related to
Sort By:
Page
of 19
Journal of Clinical Medicine
|
August 10, 2019
Detection of <i>TP53</i> and <i>PIK3CA</i> Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis
Begona Jimenez Rodriguez, Gema Diaz Córdoba, Alicia Garrido Aranda, et al.
Lancet (London, England)
|
February 2, 2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 11, 2009
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer
Stephen Chan, Gilles Romieu, Jens Huober, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 2009
Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer
Luca Gianni, José Baselga, Wolfgang Eiermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 11, 2010
Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer
Adel Tabchy, Vicente Valero, Tatiana Vidaurre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 2, 2009
Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study
Javier Cortes, Serena Di Cosimo, Miguel A Climent, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 16, 2015
Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer
Amir Sonnenblick, Prudence A Francis, Hatem A Azim, et al.
Journal of the National Cancer Institute
|
September 18, 2015
Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis
Milica Pavlovic, Anna Arnal-Estapé, Federico Rojo, et al.
The Lancet. Oncology
|
March 25, 2014
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, et al.
Cancer
|
June 7, 2005
The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study
Alberto J Montero, Roman Rouzier, Ana Lluch, et al.
Page
of 19